Pane wikiwiki
Effectively mitigate Luminex detection signal interference triggered by synthetic peptide impurities and organoid culture medium components. Master the configuration and application of spike-and-recovery experimental controls, alongside complete assay validation protocols to eliminate non-specific interference, stabilize experimental readouts and ensure accurate, repeatable biomarker detection results for cellular and organoid testing systems.
Nā Pane Luminex Cytokine ma nā haʻawina Organoid: Hoʻopilikia i ka Peptide Reagent a me nā mana hoʻokolohua

ʻEkolu manaʻo (3ʻO D) Ua hoʻololi nā ʻōnaehana organoids a me nā microfluidic neuroimmune moʻomeheu i ka loaʻa ʻana o ka lāʻau lapaʻau preclinical ma o ka hana hou ʻana i ka hoʻolālā kino kanaka., kamaʻilio pūlima, a me nā microenvironment inflammatory. E hōʻike i nā mea huna paʻakikī o ka cerebral, ʻōpū, a i ʻole nā organo tumor, hilinaʻi ka poʻe noiʻi i nā immunoassays e pili ana i ka bead multiplex—ʻoi aku ka nui o ka ʻenehana Luminex xMAP. Ma ka hopu ʻana i nā haneli o nā cytokines, chemokines, a me nā kumu ulu i ka manawa like mai nā puke hāpana minuke, hāʻawi ka multiplexing i nā ʻike kiʻekiʻe i ka hōʻailona kelepona.
Eia naʻe, ʻO ka neʻe ʻana mai nā monocultures 2D maʻamau i nā organoids 3D pilikia e hoʻolauna i nā luʻi loiloi hohonu.. ʻO nā peptides synthetic—i hoʻokomo pinepine ʻia i loko o nā moʻomeheu organoid ma ke ʻano he agonists receptor, nā mimic viral, nā neurodegenerative aggregators, a i ʻole nā lāʻau lapaʻau i manaʻo ʻia—hiki ke launa pū me nā ʻāpana hoʻāʻo multiplex ma nā ala i manaʻo ʻole ʻia. Hoʻohui ʻia me ka matrix extracellular viscous (ECM) hydrogels a me ka paʻakikī moʻomeheu media, ʻO kēia mau reagents ke kumu pinepine i ka hoʻopilikia koʻikoʻi. Me ka ʻole o nā mana hoʻokolohua ikaika, Hāʻawi kēia mau pilina biophysical i nā heluhelu cytokine artifactual, alakaʻi i nā ʻepekema e kuhi hewa i nā anomalies hoʻokele reagent no nā pane kūlohelohe maoli.
ʻO ka hoʻomaopopo ʻana i nā hana kemika ma hope o ka hoʻopili ʻana i ka peptide synthetic a me ka hoʻokō ʻana i nā hōʻoia hōʻoia quantitative he mau hana koʻikoʻi no ka hoʻokumu ʻana i ka mākaukau hoʻopaʻa loiloi., ʻikepili organoid hiki ke hana hou ʻia. ʻO nā Peptides Synthetic
riven assay anomalies no ka pane olaola maoli.
ʻO ka hoʻomaopopo ʻana i nā hana kemika ma hope o ka hoʻopili ʻana i ka peptide synthetic a me ka hoʻokō ʻana i nā hōʻoia hōʻoia quantitative he mau hana koʻikoʻi no ka hoʻokumu ʻana i ka mākaukau hoʻopaʻa loiloi., ʻikepili organoid hiki ke hana hou ʻia.
Biophysical Mechanics of Synthetic Peptide and Label Interference
Hoʻohana ka ʻenehana Luminex xMAP i ka polystyrene a i ʻole nā microspheres carboxylated magnetic (MagPlex®) hoʻoluʻu i loko me nā lakio pololei o nā fluorophores ʻulaʻula a me ka infrared. Hoʻohui ʻia kēlā me kēia pahu pahu me kahi antibody hopu kikoʻī. ʻIke ʻia nā cytokine target ma o kahi ʻano sandwich me ka hoʻohana ʻana i nā antibodies lua biotinylated a me Streptavidin-Phycoerythrin. (SAPE) conjugates mea kakau. ʻOiai paʻa, keia multi-component e like me
Nā Peptides No Gh Nui nā peptides olaola—me nā ʻāpana neurodegenerative amyloid-β, α-synuclein peptide kumu, nā neuropeptides, a me nā peptide conjugates lipidated—hōʻike i ka hydrophobicity kiʻekiʻe a i ʻole nā hana amphipathic kikoʻī. Lawe ʻia ka ʻili carboxylated o Luminex microspheres i ka ʻupena ʻino. Hiki i nā peptides synthetic hydrophobic a i hoʻopiʻi maikaʻi ʻia ke hoʻopili pono ʻole i ka ʻili o ka bead..
nā ʻāpana amyloid-β eurodegenerative, α-synuclein peptide kumu, nā neuropeptides, a me nā peptide conjugates lipidated—hōʻike i ka hydrophobicity kiʻekiʻe a i ʻole nā hana amphipathic kikoʻī. Lawe ʻia ka ʻili carboxylated o Luminex microspheres i ka ʻupena ʻino. Hiki i nā peptides synthetic hydrophobic a i hoʻopiʻi maikaʻi ʻia ke hoʻopili pono ʻole i ka ʻili o ka bead..
Hoʻokumu ʻia kēia ʻāpana kikoʻī ʻole i ʻelua mau mea hana like ʻole:
-
- Palekana Steric: ʻO nā peptides i hoʻopaʻa ʻia e hoʻopaʻa kino i nā antibodies, ka pale ʻana i nā cytokine endogenous mai ka hoʻopaʻa ʻana. ʻO kēia ka hopena i ka hoʻopunipuni ʻole a i ʻole ka helu ʻana o ka cytokine.
I nā haʻawina organoid hana, Hoʻohana pinepine ʻia nā agonists peptide synthetic ma nā ʻano micromolar kiʻekiʻe e kiʻi i nā pane kelepona.. Ina Mea hoʻoheheʻe peptide ʻO nā koena peptide koena i loko o nā organoid supernatants e noho kiʻekiʻe i ka wā o ka loiloi multiplex, hiki iā lākou ke hoʻoulu i kahi prozone (kiʻekiʻe-dose hook) hopena.
-e8e7-4401-9c35-03c745e55b85″>2. ʻO ka Prozone a me nā hopena Hook-Dose Hook
I nā haʻawina organoid hana, Hoʻohana pinepine ʻia nā agonists peptide synthetic ma nā ʻano micromolar kiʻekiʻe e kiʻi i nā pane kelepona.. Inā noho kiʻekiʻe nā koena peptide i loko o nā supernatant organoid i ka wā o ka nānā ʻana multiplex, hiki iā lākou ke hoʻoulu i kahi prozone (kiʻekiʻe-dose hook) hopena.
Ke ʻoi aku ka nui o nā peptide exogenous i ka hiki ke hoʻopaʻa i nā antibodies hopu, ʻO nā molekala peptide manuahi e hoʻopiha i nā antibodies e hopu i nā microspheres a me ka ʻike ʻana i nā antibodies i ka hopena kūʻokoʻa. Mālama kēia i ka hoʻokumu ʻana o ka paʻakikī sandwich (Bead–Capture Ab–Analyte–Detection Ab–SAPE), e hāʻule nui ana nā hōʻailona MFI me ka loaʻa ʻana o nā analyte kiʻekiʻe.
Ki Takeaway: Hiki i nā kiʻekiʻe kiʻekiʻe o ka synthetic peptide agonists ke hana i kahi hopena prozone, kahi e pale ai ka reagent keu i ka hui paʻakikī sandwich a hoʻohaʻahaʻa i nā heluhelu MFI.
3. ʻO ka inoa ʻo Fluorescent Bleed-Through and Optical Crosstalk
ʻO nā peptides synthetic i kā fluoresceinated a i ʻole fluorophore (e like me FITC, FAM, Cy5, a i ʻole Rhodamine conjugates) Hoʻohana pinepine ʻia no ka nānā ʻana i ka peptide uptake a i ʻole nā mea hoʻopaʻa paʻa i nā ʻiʻo organoid. Ke nānā ʻia kēia mau supernatants ma luna o nā paepae Luminex, ʻO nā fluorophores koena e hoʻokomo i ka hoʻopilikia optical koʻikoʻi:
- Hoʻololi Kanal Hoʻohālikelike: Hoʻokaʻawale nā mea kani Luminex i nā ʻāpana bead me ka laser diode ʻulaʻula (635 nm). ʻO nā fluorophores ʻulaʻula lōʻihi (e like me Cy5 a i ʻole Alexa Fluor 647) i hoʻopili ʻia i nā peptides synthetic hiki ke fluoresce ma luna o ka excitation laser ʻulaʻula, ka hoʻololi ʻana i ka hoʻonohonoho hoʻonohonoho ʻana i ka bead a me ka ʻike hewa ʻana i nā ʻāpana analyte.
- Kanal Kanikau-Koko: Laser ʻōmaʻomaʻo (532 nm) nā ana hoʻohauʻoli SAPE hoʻokuʻu ma 575 nm. ʻO nā hōʻailona ʻōmaʻomaʻo/melemele (e like me FITC a i ʻole FAM) ʻāwili pū me kēia spectrum ʻike, ka hana ʻana i nā hōʻailona kiʻekiʻe e hoʻohālikelike i ka kiʻekiʻe cytokine.
4. Conjugate Competition and Linker Cross-Reactivity
Hoʻohana nui ʻia ka biotinylated peptide reagents i nā haʻawina huki huki a hoʻopaʻa ʻia. Inā noho mau nā peptides biotinylated i loko o ka media i hoʻokaʻawale ʻia, hoʻokūkū pololei lākou me nā antibodies lua biotinylated no ka hoʻopaʻa ʻana iā SAPE. ʻO kēia hoʻokūkū hoʻokūkū e hōʻemi loa i ka hana hōʻailona SAPE, hoʻohaʻahaʻa wahaheʻe i nā kiʻekiʻe cytokine ma waena o ka panel multiplex holoʻokoʻa. Eia kekahi, nā mea hoʻopili synthetic-e like me nā kaulahao alkyl paʻa a i ʻole nā spacers hydrophobic-hiki ke hoʻoulu i ka hoʻopili ʻana i ka pilina pili ʻole me nā antibodies assay.
Nā hopena Matrix ma 3D Organoid a me Neuroimmune Cell Culture
Ma waho aʻe o nā mea hoʻohui peptide synthetic, ʻO ka microenvironment wai o nā organoids 3D e hoʻolauna i nā hopena matrix e hoʻololi i nā kinetics paʻa antibody a me nā microsphere fluidics..
Ua wehewehe ʻia nā Peptides i ka mea hana maʻalahi ʻO nā protein membrane basement i hoʻoheheʻe ʻia e hoʻonui i ka viscosity wai a paipai i ka microparticle aggregation.
th colspan=”1″ rowspan=”1″>
Mechanism Primary of Interference
| ʻIke ʻia ʻo Luminex Artifact | ||
|---|---|---|
| ECM Hydrogels (Matrigel, Collagen) | ʻO nā protein membrane basement i hoʻoheheʻe ʻia e hoʻonui i ka viscosity wai a paipai i ka microparticle aggregation. | Hoʻopaʻa ʻia ka paipu microfluidic, helu helu haʻahaʻa ma kēlā me kēia māhele, hoʻololi ʻia ʻo Doublet Discriminator (DD) ʻīpuka. |
| Nā mea hoʻohui moʻomeheu Media (B-27, N-2) | Nā kiʻekiʻe o ka bovine serum albumin (BSA), hormones, a me nā lipids e hoʻololi i ka ʻili. | Hoʻemi ʻia ka pilina hopu antibody, kaohi ʻana i ka hōʻailona baseline. |
| Nā mea ulu o waho (BDNF, GDNF, EGF) | Hoʻohui ʻia nā protein recombinant ma nā pae ng/mL me nā panela antibody multiplex. | ʻO nā hōʻailona maikaʻi ʻole no nā ala neurotrophic a me ka ulu ʻana. |
| Autocrine Neuroimmune Factors | Hiki ke hoʻoheheʻe cytokine a hoʻopiha i nā ʻāpana (C3a, C5a) hoʻokahe ʻia e ka neuroglia. | ʻO ka neutralization o nā cytokines i hoʻopaʻa ʻia a i ʻole ka hoʻopaʻa ʻana i nā antibodies hopu a ʻike. |
E like me ka mea i hōʻike ʻia ma nā haʻawina loiloi loiloi loiloi ka hoʻopau ʻana i ka matrix i nā hoʻokolohua cytokine multiplex, Hiki i nā matrices biological a me nā mea hoʻohui moʻomeheu ke kāohi nui i ka heluhelu cytokine i hoʻohālikelike ʻia i nā diluent assay maʻamau. Pēlā nō, noiʻi ma phycoerythrin reporter conjugate interference hōʻike i ke ʻano o ka hoʻoulu ʻana a me ka hoʻohui ʻana o ka matrix e hoʻohuli i nā hōʻailona bead multiplex.
Nā Mana Ho'āʻo Kūʻai Nui a me nā Hoʻohālikelike Matematika
E hoʻokaʻawale i ka huna cytokine maoli mai ka peptide synthetic a me ka interference matrix, Pono nā mea noiʻi organoid e hoʻokō i nā mana quantitative standardized. ʻEhā mau helu makemakika ke kumu no ka hōʻoia hōʻoia.
1. Pākēneka Spike a Ho'ōla
ʻIke ʻia ka hoʻāʻo ʻana o ka spike/recovery inā ke kāohi a hoʻomaikaʻi paha ka matrix sample a i ʻole synthetic peptide additive.. Hoʻopili ʻia kahi ʻike ʻike ʻia o ka maʻamau cytokine recombinant i loko o ka media i hoʻonohonoho ʻia organoid (loaʻa nā peptides synthetic) a me ka diluent assay maʻamau.
ʻO ke kumu hoʻōla ʻo Spike: Hoʻihoʻi hou Spike (%) = [(C_spiked_matrix − C_unspiked_matrix) ÷ C_nominal_spike] × 100%
Mahea:
- C_spiked_matrix ʻo ia ke ana ʻana i loko o ka hāpana organoid spiked.
- C_unspiked_matrix ʻo ia ka ʻike hope loa i loko o ka hāpana organoid unspiked.
- C_nominal_spike ʻO ia ka ʻike ʻike o ka cytokine i hoʻohui ʻia.
Koina ʻae: ʻO kahi hoʻihoʻi helu ma waena 80% a 120% hōʻike i ka liʻiliʻi o ka assay interference. Nā hoʻihoʻi ma lalo 80% hōʻike i ka hoʻopau ʻana i ka hōʻailona (e.g., hydrophobic adsorption a i ʻole nā hopena prozone), oiai na waiwai maluna 120% hōʻike i ka hoʻonui ʻana i ka hōʻailona kikoʻī ʻole.
2. Matrix Effect Factor (MEF)
Hoʻohālikelike ka Matrix Effect Factor i ka hopena holoʻokoʻa o ka moʻomeheu moʻomeheu a me nā mea hoʻohui peptide ma ka pali o ka curve calibration..
ʻO ke kumu hoʻohālike o ka matrix Effect Factor Formula: MEF = Slope_matrix_matched_curve ÷ Slope_neat_assay_diluent_curve
- MEF = 1.0: Nā kūlana hoʻokolohua kūpono; keakea matrix zero.
- MEF < 0.80: Kāohi matrix koʻikoʻi.
- MEF > 1.20: Hoʻonui i ka hōʻailona matrix-driven koʻikoʻi.
3. ʻO ka Linearity Dilutional a me ka Parallelism
Hōʻoia ka hoʻāʻo ʻana o Parallelism i ka hoʻemi ʻana o nā dilutions serial o ka organoid supernatant yield proportional i ka ʻike cytokine., e hōʻike ana i ka hoʻohaʻahaʻa ʻana o ka matrix me ka dilution.
ʻO ke ʻano hoʻihoʻi ʻana o Parallelism: Hoʻihoʻi Parallelism (%) = [(Ana ʻia ʻo C × DF) ÷ C_initial_neat] × 100%
Mahea DF ʻo ia ke kumu dilution. Manaʻo ʻia ka pane like ʻana ke waiho ʻia nā manaʻo i helu ʻia i loko 85% i 115% ma ka liʻiliʻi ʻekolu mau hoʻoheheʻe serial.
No ke kōkua: Inā hōʻike ka laʻana i ka hoʻihoʻi ʻole linear ma ka hoʻoheheʻe serial, hoʻonui i ka liʻiliʻi e koi ʻia dilution (MRD) me ka hoʻohana ʻana i ka mea hoʻoheheʻe matrix-matched i loaʻa nā mea hoʻopaʻa heterophilic.
4. Kea-Reactivity Index (CRI)
No ka hōʻoia ʻana ʻaʻole ʻae ʻia nā peptides synthetic me nā kahawai antibody multiplex, loiloi ʻia nā hoʻonā peptide hoʻokahi-agent ma ka ʻaoʻao piha me ka ʻole o nā cytokines.
ʻO ke kumu hoʻohālike o ka hoʻopaʻa ʻana: CRI (%) = [(MFI_peptide_alone − MFI_blank) ÷ (MFI_target_cytokine − MFI_blank)] × 100%
Koina ʻae: Pono ka Cross-Reactivity Index ma lalo 0.5% no nā awāwa cytokine āpau ʻole.
Kaʻina hoʻopaʻa hōʻoia ʻana i ka Peptide-Specific Assay Protocol
E hoʻopau pono i nā heluhelu cytokine artifactual i nā haʻawina organoid, research laboratories should implement a four-phase validation workflow prior to running experimental cohorts.
Māhele 1: Pre-Incubation Blanking
Māhele 2: Diluent Optimization & Linker Selection Phase 3: Spike/Recovery & Parallelism Validation Phase 4: Sample Pre-Treatment & Microfluidic QA
Māhele 1: Mamua-Incubation Single-Agent Blanking
Before initiating organoid perturbation experiments, test the synthetic peptide reagent alone in assay diluent across a 10-point concentration gradient (0.1 nM i 100 μM).
- Measure MFI across all multiplex channels.
- Check for fluorescent bleed-through in classification and reporter channels.
- Identify any non-specific bead binding or SAPE cross-reactivity.
- Establish the upper concentration threshold to prevent prozone suppression.
Māhele 2: ʻO ke koho ʻana i ka mea hoʻoheheʻe wai a me ke koho ʻana i ka loulou Hydrophilic
If hydrophobic adsorption or non-specific binding is observed during Phase 1:
- Modify the synthetic peptide structure by incorporating hydrophilic polyethylene glycol (PEG) mea hookui (e like me PEG₄ a i ʻole PEG₁₂) e hōʻemi i ka pilina pili pili ʻole.
- Hoʻohui i ka hoʻopaʻa hoʻāʻo me nā mea hoʻokaʻawale antibody heterophilic (e like me ka ʻiole IgG a i ʻole nā mea hoʻopaʻa pāʻoihana) a me nā surfactants non-ionic (0.05% Mawaena-20) e ālai i nā wahi kikoʻī ʻole.
Māhele 3: Holoi ʻo Matrix-Matched Spike-In a me Parallelism
E hoʻomākaukau i nā pihi maʻamau e like me ka matrix me ka hoʻohana ʻana i ka media organoid ʻole (loaʻa i nā ECM like a me nā mea hoʻohui).
- Spike haʻahaʻa, waena, a me nā kiʻekiʻe kiʻekiʻe o nā kūlana cytokine i loko o nā supernatants moʻomeheu organoid.
- E helu i ka hoʻihoʻi hou ʻana o Spike (%) a me MEF.
- Hana 1:2, 1:4, 1:8, a 1:16 nā hoʻoheheʻe serial e hoʻokumu i ka Dilution Pono Loa (MRD) e hoʻopau ana i ka hoʻopau ʻana i ka matrix me ka mālama ʻana i ka naʻau ma luna o ka Limit of Quantation (LOQ).
Māhele 4: Laʻana Pre-Treatment a me Microfluidic QA
Loaʻa pinepine ʻia nā ʻāpana microscopic hydrogel a me nā ʻōpala cell e hoʻopau i nā microfluidics Luminex..
- Centrifuge nā supernatants a pau ma 10,000 × g no 10 mau minuke ma 4°C ma mua o ka hoʻouka ʻana o ka pā.
- E hele i nā laʻana viscous 0.22 μm PVDF micro-centrifuge papa kānana.
- E hōʻoia i ka helu ʻana i ka bead i ka wā e kūʻai ai; e hōʻoia i ka loaʻa ʻana o 35-50 mau lei no kēlā me kēia māhele analyte e mālama i ka pololei helu helu.
E like me ka palapala ma ka uhi palapala nā kumu o ka ʻokoʻa ʻana i nā hoʻāʻo ʻo Luminex bead, He mea koʻikoʻi ka hoʻomākaukau ʻana i ka laʻana pre-analytical a me ka hoʻohālikelike ʻana i ka diluent maʻamau no ka mālama ʻana i ka ʻokoʻa ma waena o ka hoʻohālikelike..
Hoʻopili ʻia nā mea hoʻopaʻapaʻa: Pehea ʻo Ultra-Pure Custom Peptides e pale ai i ka walaʻau ʻana
Hoʻomaka ka pale ʻana i ka heluhelu ʻana i nā cytokine artifactual ma ke kahua synthesis kemika. ʻO nā haumia i loko o nā peptides synthetic—e like me nā kaʻina i ʻoki ʻia, peptides holoi, koena trifluoroacetic acid (TFA) nā paʻakai, a me ka lawe ʻana i ka mea hoʻoheheʻe kūlohelohe—e hoʻokele pinepine i ka hoʻopaʻa ʻana i nā bead kikoʻī ʻole a me nā mea ʻona kelepona..
I ka hoʻolālā ʻana i nā peptides synthetic no nā organoid perturbations a i ʻole nā kūlana immunoassay, ʻO ka hana pū me nā hoa hana synthesis i hōʻoia ʻia e hōʻoia i ka hilinaʻi analytical:
- Maemae Kiekie (≥98% Hōʻoia): Ke hoʻohana nei nā lawelawe hana peptide synthesis maʻamau me ka analytical Reverse-Phase HPLC (Rₛ ≥ 1.5) a me ka hōʻoia ʻana o ka ESI-MS mass spectrometry hōʻoia kiʻekiʻe e kūʻokoʻa nā kaʻina pahuhopu mai nā ʻāpana hydrophobic i ʻoki ʻia..
- Nā Koho Hoʻololi Hydrophilic: Hoʻokomo nā koho hoʻololi peptide maʻemaʻe kiʻekiʻe—me ka PEGylation pololei, hydrophilic spacers, hōʻailona isotope paʻa, a me ka hui pū ʻana o ka fluorophore kikoʻī o ka pūnaewele—pale i ka hoʻopili ʻana i nā bead kikoʻī ʻole a me ke kahe ʻana o ke kahawai optical..
- Ultra-Sterile Cleanroom Production: Ka hana ʻana i nā peptides i loko hoʻomaʻemaʻe ultra-sterile cleanroom synthesis kaiapuni (Papa 100) hoʻopau i ka pau ʻana o ka endotoxin (<0.01 EU/mg), ka pale ʻana i nā lipopolysaccharides bacteria mai ka hoʻoulu ʻana i ka huna cytokine wahaheʻe i nā organoids neuroimmune.
- Hooia-Makaukau Analytical Palapala: Loaʻa i nā palapala hōʻoia o ka ʻike (CoAs) me ka hooiaioia hōʻoia HPLC analytical a me ESI-MS hāʻawi i nā palapala e pono ai no ka hoʻokō hoʻoponopono a me nā pūʻolo ʻikepili mākaukau hoʻoponopono.
Haʻawina ma ka hoʻoneʻe ʻana o ka protein exogenous i nā panela multiplex e hoʻokūpaʻa i nā mea hoʻohui hou ʻole a i ʻole nā mea hoʻohui synthetic hiki ke hoʻololi i nā heluhelu cytokine. Ke hoʻohana ʻana i nā hiʻohiʻona piha, Hoʻopau nā peptide reagents ultra-pure i nā mea hana kemika ma ke kumu.
Papa Hoʻoponopono Hoʻonaʻauao ʻenehana no nā hoʻokolohua Organoid Multiplex
Ma mua o ka paʻi ʻana a i ʻole ka hoʻopau ʻana i nā ʻikepili cytokine mai nā haʻawina organoid perturbation, e hōʻoia i ka hoʻokō ʻana o kāu kaʻina hana hoʻokolohua i nā koina maikaʻi ma lalo nei:
| ʻĀpana hōʻoia | Pahuhopu e ae ana | Kūlana |
|---|---|---|
| Peptide Reagent Maʻemaʻe | ≥ 98% ka maʻemaʻe i hōʻoia ʻia e RP-HPLC a me ESI-MS mass spectrometry. | [ ] |
| Papa Endotoxin | < 0.01 EU/mg no ka moʻomeheu cell perturbation reagents. | [ ] |
| Hookahi-Agent Blanking | ʻAʻohe hoʻopaʻa keʻa (CRI < 0.5%) a i ʻole ka fluorophore i ke koko ma ka hana. | [ ] |
| Laki Laki/Ho'ōla | 80% ≤ Hoʻihoʻi ≤ 120% i loko o ka matrix-matched organoid supernatants. | [ ] |
| Hoʻohālikelike hoʻoheheʻe | Hoʻihoʻi laina laina i loko 85% − 115% ma waena o ≥ 3 nā hoʻoheheʻe serial consecutive. | [ ] |
| Laʻana Microfluidics | Centrifuged / kānana supernatants; ≥ 35 nā lei i loaʻa i kēlā me kēia māhele; Ua hōʻoia ʻia ka puka DD. | [ ] |
Nā ʻanuʻu aʻe no ka Assay Optimization
ʻO ka hoʻopau ʻana i nā heluhelu artifactual i ka noiʻi organoid a me neuroimmune pono e hoʻohālikelike i ka maikaʻi reagent kemika me ka hōʻoia immunoassay ikaika.. Ma ka hoʻohui ʻana i nā mana pre-incubation single-agent, nā pihi hoʻolikelike matrix-like, a me nā peptides synthetic ultra-pure, Hiki i nā hui noiʻi ke helu me ka hilinaʻi i ka hoʻoikaika cytokine maʻalahi.
No ka loiloi i nā hoʻololi peptide maʻamau, design assay-grade spike-in standards, a i ʻole e kūkākūkā me nā loea peptide synthesis e pili ana i ka koho linker hydrophilic no nā hoʻokolohua multiplex, e ʻimi i ka synthesis maʻamau a me nā mana hōʻoia maikaʻi ma MOL Changes.
